Molecular Evolution of Broadly Neutralizing Llama Antibodies to the CD4-Binding Site of HIV-1

To date, no immunization of humans or animals has elicited broadly neutralizing sera able to prevent HIV-1 transmission; however, elicitation of broad and potent heavy chain only antibodies (HCAb) has previously been reported in llamas. In this study, the anti-HIV immune responses in immunized llamas were studied via deep sequencing analysis using broadly neutralizing monoclonal HCAbs as a guides. Distinct neutralizing antibody lineages were identified in each animal, including two defined by novel antibodies (as variable regions called VHH) identified by robotic screening of over 6000 clones. The combined application of five VHH against viruses from clades A, B, C and CRF_AG resulted in neutralization as potent as any of the VHH individually and a predicted 100% coverage with a median IC50 of 0.17 µg/ml for the panel of 60 viruses tested. Molecular analysis of the VHH repertoires of two sets of immunized animals showed that each neutralizing lineage was only observed following immunization, demonstrating that they were elicited de novo. Our results show that immunization can induce potent and broadly neutralizing antibodies in llamas with features similar to human antibodies and provide a framework to analyze the effectiveness of immunization protocols.

[1]  Neutralisation of HIV-1 cell-cell spread by human and llama antibodies , 2014, Retrovirology.

[2]  Chaim A. Schramm,et al.  Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies , 2014, Nature.

[3]  J. Mascola,et al.  Single-Cell and Deep Sequencing of IgG-Switched Macaque B Cells Reveal a Diverse Ig Repertoire following Immunization , 2014, The Journal of Immunology.

[4]  Richard Wilson,et al.  Vaccine-elicited primate antibodies use a distinct approach to the HIV-1 primary receptor binding site informing vaccine redesign , 2014, Proceedings of the National Academy of Sciences.

[5]  L. Stamatatos,et al.  Soluble HIV-1 Envelope Immunogens Derived from an Elite Neutralizer Elicit Cross-Reactive V1V2 Antibodies and Low Potency Neutralizing Antibodies , 2014, PloS one.

[6]  L. Stamatatos,et al.  Diverse Recombinant HIV-1 Envs Fail To Activate B Cells Expressing the Germline B Cell Receptors of the Broadly Neutralizing Anti-HIV-1 Antibodies PG9 and 447-52D , 2013, Journal of Virology.

[7]  Michael S. Seaman,et al.  Therapeutic Efficacy of Potent Neutralizing HIV-1-Specific Monoclonal Antibodies in SHIV-Infected Rhesus Monkeys , 2013, Nature.

[8]  L. Morris,et al.  Viral Escape from HIV-1 Neutralizing Antibodies Drives Increased Plasma Neutralization Breadth through Sequential Recognition of Multiple Epitopes and Immunotypes , 2013, PLoS pathogens.

[9]  Young Do Kwon,et al.  Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies. , 2013, Immunity.

[10]  L. Stamatatos,et al.  Correction: Recombinant HIV Envelope Proteins Fail to Engage Germline Versions of Anti-CD4bs bNAbs , 2013, PLoS Pathogens.

[11]  R. Wyatt,et al.  Independent Expansion of Epitope-Specific Plasma Cell Responses upon HIV-1 Envelope Glycoprotein Immunization , 2013, The Journal of Immunology.

[12]  R. Rance,et al.  Network properties derived from deep sequencing of human B-cell receptor repertoires delineate B-cell populations , 2013, Genome research.

[13]  Q. Sattentau,et al.  Anti-HIV IgA isotypes: differential virion capture and inhibition of transcytosis are linked to prevention of mucosal R5 SHIV transmission , 2013, AIDS.

[14]  David Nemazee,et al.  Rational immunogen design to target specific germline B cell receptors , 2012, Retrovirology.

[15]  L. Stamatatos,et al.  Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies , 2013, The Journal of experimental medicine.

[16]  M. Nussenzweig,et al.  Structural basis for HIV-1 gp120 recognition by a germ-line version of a broadly neutralizing antibody , 2013, Proceedings of the National Academy of Sciences.

[17]  Chaim A. Schramm,et al.  Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus , 2013, Nature.

[18]  W. Weissenhorn,et al.  A gp41 MPER-specific Llama VHH Requires a Hydrophobic CDR3 for Neutralization but not for Antigen Recognition , 2013, PLoS pathogens.

[19]  Robin A. Weiss,et al.  Neutralizing antibodies to HIV-1 induced by immunization , 2013, The Journal of experimental medicine.

[20]  Guido Ferrari,et al.  Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. , 2013, Immunity.

[21]  L. Stamatatos,et al.  Recombinant HIV Envelope Proteins Fail to Engage Germline Versions of Anti-CD4bs bNAbs , 2013, PLoS pathogens.

[22]  Ron Diskin,et al.  HIV therapy by a combination of broadly neutralizing antibodies in humanized mice , 2012, Nature.

[23]  J. Bouchet,et al.  Straightforward Selection of Broadly Neutralizing Single-Domain Antibodies Targeting the Conserved CD4 and Coreceptor Binding Sites of HIV-1 gp120 , 2012, Retrovirology.

[24]  Lynn Morris,et al.  Evolution of an HIV glycan–dependent broadly neutralizing antibody epitope through immune escape , 2012, Nature Medicine.

[25]  D. Burton,et al.  Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo , 2012, Proceedings of the National Academy of Sciences.

[26]  D. Baltimore,et al.  Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission , 2012, Retrovirology.

[27]  M. Nussenzweig,et al.  Structural basis for germline gene usage of a potent class of antibodies targeting the CD4 binding site of HIV-1 gp120 , 2012, Retrovirology.

[28]  Ron Diskin,et al.  Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120 , 2012, Proceedings of the National Academy of Sciences.

[29]  R. Weiss,et al.  Potent and broad neutralization of HIV-1 by a llama antibody elicited by immunization , 2012, The Journal of experimental medicine.

[30]  Hasan Ahmed,et al.  Magnitude and Breadth of the Neutralizing Antibody Response in the RV144 and Vax003 HIV-1 Vaccine Efficacy Trials , 2012, The Journal of infectious diseases.

[31]  Guido Ferrari,et al.  Immune-correlates analysis of an HIV-1 vaccine efficacy trial. , 2012, The New England journal of medicine.

[32]  R. Weiss,et al.  Llama Antibody Fragments Recognizing Various Epitopes of the CD4bs Neutralize a Broad Range of HIV-1 Subtypes A, B and C , 2012, PloS one.

[33]  Tongqing Zhou,et al.  PGV04, an HIV-1 gp120 CD4 Binding Site Antibody, Is Broad and Potent in Neutralization but Does Not Induce Conformational Changes Characteristic of CD4 , 2012, Journal of Virology.

[34]  R. Weiss,et al.  Llama antibody fragments have good potential for application as HIV type 1 topical microbicides. , 2012, AIDS research and human retroviruses.

[35]  T. Kepler,et al.  Two Distinct Broadly Neutralizing Antibody Specificities of Different Clonal Lineages in a Single HIV-1-Infected Donor: Implications for Vaccine Design , 2012, Journal of Virology.

[36]  Michael S. Seaman,et al.  HIV-1 Neutralization Coverage Is Improved by Combining Monoclonal Antibodies That Target Independent Epitopes , 2012, Journal of Virology.

[37]  David Baltimore,et al.  Antibody-based Protection Against HIV Infection by Vectored ImmunoProphylaxis , 2011, Nature.

[38]  C. MacKenzie,et al.  Semiautomated panning of naive camelidae libraries and selection of single-domain antibodies against peptide antigens. , 2012, Methods in molecular biology.

[39]  Ron Diskin,et al.  Increasing the Potency and Breadth of an HIV Antibody by Using Structure-Based Rational Design , 2011, Science.

[40]  Pham Phung,et al.  Broad neutralization coverage of HIV by multiple highly potent antibodies , 2011, Nature.

[41]  Ron Diskin,et al.  Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding , 2011, Science.

[42]  Brigitte E. Sanders-Beer,et al.  Prevention of vaginal SHIV transmission in macaques by a live recombinant Lactobacillus , 2011, Mucosal Immunology.

[43]  L. Hammarström,et al.  Lactobacilli producing bispecific llama-derived anti-rotavirus proteins in vivo for rotavirus-induced diarrhea. , 2011, Future microbiology.

[44]  M. Humbert,et al.  An Anti-HIV-1 V3 Loop Antibody Fully Protects Cross-Clade and Elicits T-Cell Immunity in Macaques Mucosally Challenged with an R5 Clade C SHIV , 2011, PloS one.

[45]  Cedric E. Ginestet.  ggplot2: Elegant Graphics for Data Analysis , 2011 .

[46]  Lynn Morris,et al.  Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women , 2010, Science.

[47]  Mario Roederer,et al.  Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1 , 2010, Science.

[48]  Tongqing Zhou,et al.  Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01 , 2010, Science.

[49]  A MarioCalvo,et al.  Vaccination with ALVAC and AIDS-VAX to prevent HIV-1 infection in Thailand , 2010 .

[50]  Q. Sattentau,et al.  Analysis of Memory B Cell Responses and Isolation of Novel Monoclonal Antibodies with Neutralizing Breadth from HIV-1-Infected Individuals , 2010, PloS one.

[51]  Jerome H. Kim,et al.  Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. , 2009, The New England journal of medicine.

[52]  Holly Janes,et al.  Tiered Categorization of a Diverse Panel of HIV-1 Env Pseudoviruses for Assessment of Neutralizing Antibodies , 2009, Journal of Virology.

[53]  Pham Phung,et al.  Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target , 2009, Science.

[54]  Hadley Wickham,et al.  ggplot2 - Elegant Graphics for Data Analysis (2nd Edition) , 2017 .

[55]  D. Dimitrov,et al.  Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: Implications for evasion of immune responses and design of vaccine immunogens , 2009, Biochemical and Biophysical Research Communications.

[56]  D. Burton,et al.  Broadly Neutralizing Human Anti-HIV Antibody 2G12 Is Effective in Protection against Mucosal SHIV Challenge Even at Low Serum Neutralizing Titers , 2009, PLoS pathogens.

[57]  R. Weiss,et al.  Llama Antibody Fragments with Cross-Subtype Human Immunodeficiency Virus Type 1 (HIV-1)-Neutralizing Properties and High Affinity for HIV-1 gp120 , 2008, Journal of Virology.

[58]  S. Plotkin,et al.  Vaccines: correlates of vaccine-induced immunity. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[59]  Gábor Csárdi,et al.  The igraph software package for complex network research , 2006 .

[60]  Peter D. Kwong,et al.  HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites , 2002, Nature.

[61]  M. Graf,et al.  Concerted Action of Multiple cis-Acting Sequences Is Required for Rev Dependence of Late Human Immunodeficiency Virus Type 1 Gene Expression , 2000, Journal of Virology.

[62]  J. Mascola,et al.  Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies , 2000, Nature Medicine.

[63]  J. Mascola,et al.  Protection of Macaques against Pathogenic Simian/Human Immunodeficiency Virus 89.6PD by Passive Transfer of Neutralizing Antibodies , 1999, Journal of Virology.

[64]  H. Katinger,et al.  Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. , 1999, Immunity.

[65]  S. Muyldermans,et al.  Naturally occurring antibodies devoid of light chains , 1993, Nature.

[66]  E. Myers,et al.  Basic local alignment search tool. , 1990, Journal of molecular biology.